Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Neoplasm Metastasis 2Uterine Cervical Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Gliosarcoma 1Glioblastoma 1

Interventions

Pemetrexed 8pembrolizumab 6Cisplatin 6LMB-100 3Carboplatin 3Radiosurgery 2Plicamycin 2Dexamethasone 2Cryotherapy 2vandetanib 1tremelimumab 1tocilizumab 1rebastinib 1pevonedistat 1perflutren 1nintedanib 1iodixanol 1fludarabine phosphate 1fludarabine 1epacadostat 1enzalutamide 1durvalumab 1defactinib 1anetumab ravtansine 1amatuximab 1alvocidib 1aldesleukin 1Vinorelbine 1Sulfur Hexafluoride 1Radiotherapy, Intensity-Modulated 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Mesothelioma × Automobiles × Clear all
NCT01583686 2019-10-14

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
15 enrolled 14 charts
GastrointestinalGynecologicOther solid neoplasmThoracic

Uterine Cervical Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡